JAC Advance Access published online on January 3, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm499
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article |
Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
1 Immunodeficiency Clinic, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Canada M5G 2C4 2 Department of Psychiatry, University of Toronto, 200 Elizabeth Street, Toronto, Canada M5G 2C4 3 Division of Infectious Diseases, University of Toronto, 200 Elizabeth Street, Toronto, Canada M5G 2C4
* Corresponding author. Tel: +1-416-340-4800 ext. 8609; Fax: +1-416-340-4890; E-mail: bob.burgoyne{at}uhn.on.ca
Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of disease progression in eroding quality of life (QOL) erosion in the pre-HAART age is now supplanted by drug toxicities, one of the Achilles heels of HAART. This article reviews research findings on treatment and QOL outcomes a decade into the HAART era.
Key Words: AIDS , drug toxicities , QOL